

Supplementary Material (ESI) for Chemical Communications
This journal is (c) The Royal Society of Chemistry 2011

Electronic Supporting Information

A new tool to assess ceramide bioactivity: 6-bromo-7-hydroxycoumarinyl-caged ceramide

Young Ah Kim,^a Daniel M. Carter Ramirez,^{b,c} Willard J. Costain,^d Linda J. Johnston^b and Robert Bittman^{*a}

^aDepartment of Chemistry and Biochemistry, Queens College of The City University of New York, Flushing, NY 11367, USA.

E-mail: robert.bittman@qc.cuny.edu

^bSteacie Institute for Molecular Sciences, National Research Council of Canada, Ottawa, ON K1A 0R6, CANADA

^cDepartment of Chemistry, University of Ottawa, Ottawa, ON K1N 6N5, CANADA

^dInstitute for Biological Sciences, National Research Council of Canada, Ottawa, ON K1A 0R6, CANADA

Table of Contents

General synthetic methods	S2
Absorption and fluorescence spectroscopy	S2
Photolysis and photoproduct analysis	S3
Synthesis of 6-bromo-4-(chloromethyl)-7-hydroxycoumarin (3)	S3
Synthesis of 6-bromo-7-hydroxy-4-hydroxymethylcoumarin (4)	S4
Synthesis of 6-bromo-7- <i>O</i> -(methoxymethyl)-4-hydroxymethylcoumarin (5)	S4
Synthesis of 6-bromo-7- <i>O</i> -(methoxymethyl)coumarin-4-ylmethoxycarbonyl chloride (6)	S5
Synthesis of (2 <i>S</i> ,3 <i>R</i> ,4 <i>E</i>)-2-butyramido-3-hydroxyoctadec-4-enyl (6-bromo-7- <i>O</i> -(methoxymethyl)coumarin-4-yl)methyl carbonate (8a) and (2 <i>S</i> ,3 <i>R</i> ,4 <i>E</i>)-2-butyramido-octadec-4-ene-1,3-diyl bis(6-bromo-7- <i>O</i> -(methoxymethyl)coumarin-4-yl)methyl dicarbonate (8b)	S5
Synthesis of (2 <i>S</i> ,3 <i>R</i> ,4 <i>E</i>)-2-palmitoylamido-3-hydroxyoctadec-4-enyl (6-bromo-7- <i>O</i> -(methoxymethyl)coumarin-4-yl)methyl carbonate (12)	S7
Synthesis of (2 <i>S</i> ,3 <i>R</i>)-2-palmitoylamido-3-hydroxyoctadecyl (6-bromo-7- <i>O</i> -(methoxymethyl)coumarin-4-yl)methyl carbonate (15)	S8
General procedure for removal of the MOM protecting group to generate 6-bromo-7-hydroxycoumarin-4-ylmethyl (Bhc) caged ceramides (9 , 10 , 13 , and 16)	S9
Synthesis of (2 <i>S</i> ,3 <i>R</i> ,4 <i>E</i>)-2-butyramido-3-hydroxyoctadec-4-enyl (6-bromo-7-hydroxycoumarin-4-yl)methyl carbonate (9)	S9
Synthesis of (2 <i>S</i> ,3 <i>R</i> ,4 <i>E</i>)-2-butyramido-octadec-4-ene-1,3-diyl bis(6-bromo-7-hydroxycoumarin-4-yl)methyl dicarbonate (10)	S10
Synthesis of (2 <i>S</i> ,3 <i>R</i> ,4 <i>E</i>)-2-palmitoylamido-3-hydroxyoctadec-4-enyl (6-bromo-7-hydroxycoumarin-4-yl)methyl carbonate (13)	S11
Synthesis of (2 <i>S</i> ,3 <i>R</i>)-2-palmitoylamido-3-hydroxyoctadecyl (6-bromo-7-hydroxycoumarin-4-yl)methyl carbonate (16)	S11
Preparation of silica-supported sodium hydrogen sulfate (NaHSO ₄ ·SiO ₂) catalyst	S12
Uptake of compound 16 into J774 macrophages	S12
Fig. S1. UV-visible absorption spectra of Bhc-caged ceramides in CHCl ₃ /EtOH (4:1). (a) compound 9 , (b) compound 10 , (c) compound 13 , and (d) compound 16	S13
Fig. S2. Absorption (top) and fluorescence emission (bottom) spectra of 4 in KMops buffer, pH 7.4, (4A), and 4 and 16 in KMops containing 50% EtOH (4B and 16B, respectively)	S14
Fig. S3 Uptake of compound 16 by macrophages and time course of photorelease of 4 upon photolysis	S15
Fig. S4 UV irradiation of J774 macrophages in the absence of 16 (control)	S16
Fig. S5 Release of C16-dihydroceramide from 16 on photolysis at 350 nm	S17
References	S17

Mass spectra of compounds (**8a**, **8b**, **12**, **15**, **9**, **10**, **13**, and **16**)

S18-S34

NMR spectra of compounds (**3**, **4**, **5**, **6**, **8a**, **8b**, **12**, **15**, **9**, **10**, **13**, and **16**)


S35-S54

General synthetic methods. Optical rotation was determined on an Autopol III Automatic Polarimeter. High-resolution mass spectra were recorded on an Agilent Technologies G6520A Q-TOF mass spectrometer using electrospray ionization. NMR spectra were recorded on Bruker Avance I and III spectrometers (400 or 500 MHz), and chemical shifts are expressed in parts per million (δ) relative to chloroform (7.26 ppm for ^1H and 77.2 ppm for ^{13}C), methanol (3.31 ppm for ^1H and 49.0 ppm for ^{13}C) or DMSO (2.50 ppm for ^1H and 40.0 ppm for ^{13}C) as an internal reference. TLC was performed on 0.25-mm silica gel 60 F₂₅₄ aluminum-backed plates. Silica gel 60 (230-400 mesh) was used for flash column chromatography. The compounds were visualized by UV light and 10% phosphomolybdic acid in ethanol. THF was distilled from sodium and benzophenone, and hexane and CH_2Cl_2 were dried over calcium hydride. C4-Ceramide (*N*-butyroyl-D-*erythro*-sphingosine, d18:1/4:0) and C16-ceramide (*N*-palmitoyl-D-*erythro*-sphingosine, d18:1/16:0) were purchased from Avanti Polar Lipids. Flash chromatography was performed using a Biotage Isolera One automated system with Flash KP-Sil™ silica cartridges. Preparative TLC was carried out using 1000- μm silica gel GF from Analtech.

Absorption and fluorescence spectroscopy. Absorption spectra were measured with a Cary 5000 UV-vis-NIR spectrophotometer. Emission spectra were recorded using a Horiba Jobin Yvon FL-3 21 2tau spectrofluorometer with slit widths of 1 nm. All spectral measurements were performed at 22 °C using a 1-cm pathlength quartz cuvette. Fluorescence quantum yields were calculated with reference to Coumarin 460 in ethanol ($\Phi_{\text{fl}} = 0.59$)^{S1} at an excitation wavelength of 374 nm and absorbance ≤ 0.1 . Working solutions of the compounds were prepared at 5-10 μM to match the absorbance of 5 μM Coumarin 460 at 374 nm.


Photolysis and photoproduct analysis. Photolysis was performed in a quartz cuvette containing 3 mL of 5 μ M caged substrate in 10 mM KMops buffer containing 100 mM KCl (pH 7.4) with 50% ethanol. The sample was irradiated at 350 nm in a Rayonet photochemical reactor (Southern New England Ultraviolet Co., Branford, CT, USA) equipped with four lamps. Aliquots of 20 μ L were removed periodically for analysis. Coumarin 480 was added to each aliquot as an internal standard. Loss of starting material and formation of by-product **4** were monitored by reversed-phase HPLC with a SunFire C18 column (Waters Corp., Milford, MA, USA), and eluted with an ethanol/water gradient at a flow rate of 0.8 mL/min. Detection was by absorbance at 325 nm and fluorescence at 480 nm.

6-Bromo-4-(chloromethyl)-7-hydroxycoumarin (3**).**




A solution of 4-bromoresorcinol **1** (1.00 g, 5.29 mmol) in methanesulfonic acid (8.0 mL) was treated with methyl 4-chloroacetoacetate **2** (0.92 mL, 7.94 mmol) and then was stirred for 2 h at room temperature. The resulting mixture was slowly poured into ice-water (24 mL) and then was stirred for 30 min to give a white precipitate. The precipitate was collected by filtration and washed with cold water (3 $\times$ 5 mL). The resulting precipitate was recrystallized with hexane/EtOAc to give compound **3** (1.46 g, 95%): R_f 0.17 (hexane/EtOAc 3:1); ^1H NMR (400 MHz; DMSO- d_6) δ_{H} 5.00 (2H, m), 6.47 (1H, s), 6.92 (1H, s), 7.99 (1H, s), 11.57 (1H, br); ^{13}C NMR (100 MHz; DMSO- d_6) δ_{C} 41.2, 103.3, 106.2, 110.7, 112.1, 129.1, 150.2, 154.1, 157.6, 159.7.

6-Bromo-7-hydroxy-4-hydroxymethylcoumarin (4).




A suspension of compound **3** (1.04 g, 3.59 mmol) in water (250 mL) was heated at reflux for 2 days and allowed to cool to room temperature. The resulting mixture was concentrated *in vacuo*, and then the residue was triturated with hexane/Et₂O (2:1, 6 mL) to afford compound **4** (0.96 g, 99%). The resulting compound **4** was used in the next step without further purification: *R_f* 0.80 (EtOAc); ¹H NMR (400 MHz; CD₃OD) δ_H 4.77 (2H, m), 6.38 (1H, s), 6.84 (1H, s), 7.81 (1H, s); ¹³C NMR (100 MHz; CD₃OD) δ_C 60.8, 104.2, 107.8, 109.1, 112.7, 129.3, 155.5, 157.2, 158.9, 163.3.

6-Bromo-7-O-(methoxymethyl)-4-hydroxymethylcoumarin (5).



A mixture of compound **4** (0.80 g, 2.95 mmol) and *N,N*-diisopropylethylamine (DIPEA, 0.57 mL, 2.88 mmol) in dry CH₂Cl₂ (30 mL) was cooled to 0 °C, and then chloromethyl methyl ether (MOMCl, 0.25 mL, 2.88 mmol) was added dropwise. After being stirred for 2 h at 0 °C, the reaction mixture was poured into 0.5 M citric acid (20 mL) and extracted with CHCl₃ (2 × 20 mL). The combined organic layer was washed with brine (30 mL) and dried over Na₂SO₄. After the solvent was removed *in vacuo*, the residue was triturated with hexane (2 × 5 mL) to afford compound **5** (0.83 g, 89%): *R_f* 0.34 (hexane/EtOAc 1:1); ¹H NMR (400 MHz; CDCl₃) δ_H 2.05 (1H, t, *J* = 4.9 Hz), 3.52 (3H, s), 4.86 (2H, m), 5.32 (2H, s), 6.52 (1H, s), 7.16 (1H, s), 7.70 (1H, s); ¹³C NMR (100 MHz; CDCl₃) δ_C 56.8, 60.9, 95.3, 104.2, 108.5, 110.6, 112.9, 127.6, 152.9, 154.3, 156.3, 160.8; HRMS [*M*+H]⁺ *m/z* calcd for C₁₂H₁₂BrO₅ 314.9863, found 314.9863.

6-Bromo-7-*O*-(methoxymethyl)coumarin-4-ylmethoxycarbonyl chloride (6).




A mixture of triphosgene (0.53 g, 1.79 mmol) and Aliquat^R 336 (63 μ L, 0.14 mmol) in dry hexane (1.5 mL) was stirred at room temperature for 16 h in a pressure tube (bushing type back seal) to generate phosgene. To a suspension of compound **5** (86.7 mg, 0.28 mmol) in dry THF/toluene (3:2, 1.5 mL) was added the phosgene solution at 0 °C. The resulting mixture was stirred 3 h at 0 °C and then the solvent was removed *in vacuo*. The residue was triturated with hexane/ CH_2Cl_2 (3:1, 2×1 mL) to afford the corresponding chloroformate **6** (97.6 mg, 94%). The resulting compound **6** was used in the next step without further purification: R_f 0.87 (hexane/EtOAc 1:1); ^1H NMR (400 MHz; CDCl_3) δ_{H} 3.53 (3H, s), 5.33 (2H, s), 5.41 (2H, m), 6.44 (1H, s), 7.19 (1H, s), 7.64 (1H, s); ^{13}C NMR (100 MHz; CDCl_3) δ_{C} 56.9, 67.2, 95.3, 104.4, 109.0, 111.9, 112.8, 127.4, 145.4, 150.8, 154.4, 156.9, 159.7.

(2*S*,3*R*,4*E*)-2-Butyramido-3-hydroxyoctadec-4-enyl (6-bromo-7-*O*-(methoxymethyl)coumarin-4-yl)methyl carbonate (8a) and (2*S*,3*R*,4*E*)-2-butyramido-octadec-4-ene-1,3-diyl bis(6-bromo-7-*O*-(methoxymethyl)coumarin-4-yl)methyl dicarbonate (8b).


To a mixture of C4-ceramide **7** (*N*-butyroyl-D-*erythro*-sphingosine (d18:1/4:0), 10 mg, 27 μ mol) and 6-bromo-7-*O*-(methoxymethyl)coumarin-4-ylmethoxycarbonyl chloride **6** (11 mg, 30 μ mol) in dry CH_2Cl_2 (3.0 mL) were added DIPEA (5.2 μ L, 30 μ mol) and 4-(dimethylamino)pyridine (DMAP, 3.3 mg, 27 μ mol) at 0 °C. The reaction mixture was stirred for 2.5 h at 0 °C and then was concentrated *in vacuo*.

The residue was purified in a Biotage Isolera One flash purification system with hexane/EtOAc gradient

elution to afford mono-Bhc-caged C4-ceramide **8a** (10.4 mg, 54%) and di-Bhc-caged C4-ceramide **8b** (4.0 mg, 14%).




8a: R_f 0.36 (hexane/EtOAc 1:1); $[\alpha]_D^{29}$ -0.6 (c 0.58 in $\text{CHCl}_3/\text{MeOH}$ 4:1); ^1H NMR (400 MHz; CDCl_3) δ_{H} 0.88 (3H, t, $J = 6.8$ Hz), 0.95 (3H, t, $J = 7.4$ Hz), 1.25 (20H, m), 1.33 (2H, m), 1.66 (2H, m), 2.05 (2H, m), 2.20 (2H, t, $J = 7.4$ Hz), 2.50 (1H, br), 3.52 (3H, s), 4.26 (2H, m), 4.35 (1H, dd, $J_1 = 11.2$ Hz, $J_2 = 3.4$ Hz), 4.47 (1H, dd, $J_1 = 11.2$ Hz, $J_2 = 5.6$ Hz), 5.28 (2H, m), 5.32 (2H, s), 5.51 (1H, dd, $J_1 = 15.4$ Hz, $J_2 = 6.5$ Hz), 5.78 (1H, dt, $J_1 = 15.4$ Hz, $J_2 = 6.7$ Hz), 5.91 (1H, d, $J = 8.0$ Hz), 6.43 (1H, s), 7.17 (1H, s), 7.67 (1H, s); ^{13}C NMR (100 MHz; CDCl_3) δ_{C} 13.8, 14.3, 19.2, 22.8, 29.2, 29.4, 29.5, 29.6, 29.8, 32.1, 32.4, 38.8, 52.6, 56.9, 64.4, 67.4, 73.1, 95.3, 104.2, 108.8, 111.8, 112.3, 127.5, 128.4, 135.4, 147.4, 154.3, 154.5, 156.6, 160.1, 173.5; HRMS $[\text{M}+\text{H}]^+$ m/z calcd for $\text{C}_{35}\text{H}_{53}^{79}\text{BrNO}_9$ 710.2898, found 710.2901.



8b: R_f 0.38 (hexane:EtOAc 1:1); $[\alpha]_D^{28}$ -9.2 (c 0.59 in $\text{CHCl}_3/\text{MeOH}$ 4:1); ^1H NMR (400 MHz; CDCl_3) δ_{H} 0.87 (3H, t, $J = 6.8$ Hz), 0.94 (3H, t, $J = 7.4$ Hz), 1.24 (20H, m), 1.35 (2H, m), 1.66 (2H, m), 2.06

(2H, m), 2.19 (2H, t, $J = 7.4$ Hz), 3.52 (6H, s), 4.27 (1H, m), 4.54 (1H, m), 4.56 (1H, m), 5.20 (1H, m), 5.27 (2H, m), 5.28 (2H, m), 5.32 (4H, s), 5.47 (1H, dd, $J_1 = 15.4$ Hz, $J_2 = 8.0$ Hz), 5.81 (1H, d, $J = 8.6$ Hz), 5.94 (1H, dt, $J_1 = 15.3$ Hz, $J_2 = 6.8$ Hz), 6.40 (1H, s), 6.42 (1H, s), 7.15 (1H, s), 7.16 (1H, s), 7.67 (1H, s), 7.68 (1H, s); ^{13}C NMR (100 MHz; CDCl_3) δ_{C} 13.8, 14.3, 19.2, 22.8, 28.9, 29.4, 29.5, 29.6, 29.8, 32.1, 32.5, 38.7, 50.3, 56.9, 64.5, 64.7, 66.8, 78.8, 95.3, 104.2, 108.8, 111.8, 112.3, 123.2, 127.6, 139.8, 147.3, 147.4, 153.7, 154.3, 154.4, 156.6, 160.0, 172.9; HRMS $[\text{M}+\text{H}]^+$ m/z calcd for $\text{C}_{48}\text{H}_{62}^{79}\text{Br}_2\text{NO}_{15}$ 1050.2481, found 1050.2470.


(2*S*,3*R*,4*E*)-2-Palmitoylamido-3-hydroxyoctadec-4-enyl (6-bromo-7-*O*-(methoxymethyl)coumarin-4-yl)methyl carbonate (12).



To a mixture of C16-ceramide **11** (*N*-palmitoyl-D-*erythro*-sphingosine (d18:1/16:0), 10 mg, 19 μmol) and 6-bromo-7-*O*-(methoxymethyl)coumarin-4-ylmethoxycarbonyl chloride **6** (7.7 mg, 20 μmol) in dry THF/ CH_2Cl_2 (2:1, 3.0 mL) were added DIPEA (3.6 μL , 20 μmol) and DMAP (2.3 mg, 19 μmol). The reaction mixture was stirred at room temperature for 36 h and then was concentrated *in vacuo*. Purification of the residue in a Biotage Isolera One flash purification system with hexane/EtOAc gradient elution afforded mono-Bhc-caged C16-ceramide **12** (4.1 mg, 25%): R_f 0.33 (hexane/EtOAc

2:1); $[\alpha]_D^{27} +11.0$ (*c* 0.31 in CHCl_3); ^1H NMR (400 MHz; CDCl_3) δ_{H} 0.88 (6H, t, $J = 6.8$ Hz), 1.25 (46H, m), 1.33 (2H, m), 1.62 (2H, m), 2.04 (2H, m), 2.21 (2H, t, $J = 7.6$ Hz), 2.37 (1H, br), 3.52 (3H, s), 4.25 (2H, m), 4.35 (1H, dd, $J_1 = 11.2$ Hz, $J_2 = 3.4$ Hz), 4.48 (1H, dd, $J_1 = 11.2$ Hz, $J_2 = 5.4$ Hz), 5.28 (2H, m), 5.32 (2H, s), 5.51 (1H, dd, $J_1 = 15.4$ Hz, $J_2 = 6.5$ Hz), 5.78 (1H, dt, $J_1 = 15.3$ Hz, $J_2 = 6.7$ Hz), 5.84 (1H, d, $J = 8.0$ Hz), 6.43 (1H, s), 7.18 (1H, s), 7.67 (1H, s); ^{13}C NMR (125 MHz; CDCl_3) δ_{C} 14.3, 22.8, 25.8, 29.4, 29.5, 29.7, 29.8, 32.1, 32.4, 37.0, 52.6, 56.9, 64.5, 67.4, 73.1, 95.3, 104.2, 108.8, 111.8, 112.3, 127.5, 128.4, 135.5, 147.4, 154.3, 154.5, 156.6, 160.1, 173.7; HRMS $[\text{M}+\text{H}]^+ m/z$ calcd for $\text{C}_{47}\text{H}_{77}^{79}\text{BrNO}_9$ 878.4776, found 878.4772.

(2*S*,3*R*)-2-Palmitoylamido-3-hydroxyoctadecyl (6-bromo-7-*O*-(methoxymethyl)coumarin-4-yl)methyl carbonate (15).




C16-Dihydroceramide **14** (*N*-palmitoyl-D-*erythro*-sphingosine (d18:0/16:0), 10 mg, 19 μmol) was converted to compound **15** (4.4 mg, 27%) using the same procedure as described for compound **12**: R_f 0.34 (hexane/EtOAc 2:1); $[\alpha]_D^{29} +11.4$ (*c* 0.99 in CHCl_3); ^1H NMR (400 MHz; CDCl_3) δ_{H} 0.88 (6H, t, $J = 6.7$ Hz), 1.25 (50H, m), 1.52 (2H, m), 1.63 (2H, m), 2.23 (2H, m), 2.47 (1H, br), 3.52 (3H, s), 4.15 (1H, m), 4.26 (1H, m), 4.38 (1H, dd, $J_1 = 11.3$ Hz, $J_2 = 3.3$ Hz), 4.51 (1H, m), 5.28 (2H, m), 5.32 (2H, s),

6.01 (1H, d, $J = 8.5$ Hz), 6.43 (1H, s), 7.17 (1H, s), 7.67 (1H, s); ^{13}C NMR (100 MHz; CDCl_3) δ_{C} 14.3, 22.8, 25.9, 29.5, 29.6, 29.7, 29.8, 32.1, 34.4, 40.0, 52.6, 56.9, 64.5, 67.6, 68.4, 72.4, 83.3, 95.3, 104.2, 108.8, 111.8, 112.3, 127.5, 147.4, 154.3, 154.6, 156.7, 160.1, 173.6; HRMS $[\text{M}+\text{H}]^+$ m/z calcd for $\text{C}_{47}\text{H}_{79}^{79}\text{BrNO}_9$ 880.4933, found 880.4941.

General Procedure for Removal of the MOM Protecting Group to Generate 6-Bromo-7-hydroxycoumarin-4-ylmethyl (Bhc) Caged Ceramides (9, 10, 13, and 16).

To a solution of 4 μmol of MOM-Bhc-caged ceramide (**8a**, **8b**, **12**, or **15**) in 2.0 mL of dry CH_2Cl_2 was added 3 mg of silica-supported sodium hydrogen sulfate ($\text{NaHSO}_4 \cdot \text{SiO}_2$) at room temperature. The reaction mixture was stirred at room temperature until the starting material was no longer observed (~2 h, as monitored by TLC). The catalyst was removed by filtration, and the filtrate was concentrated *in vacuo*. The residue was purified by preparative TLC ($\text{CHCl}_3/\text{MeOH}$ 9:1) to afford the corresponding product, which was dissolved in CHCl_3 and passed through a 0.45- μm syringe filter to remove the suspended silica gel.


(2*S*,3*R*,4*E*)-2-Butyramido-3-hydroxyoctadec-4-enyl (6-bromo-7-hydroxycoumarin-4-yl)methyl carbonate (9).



Yield 73%; UV ($\text{CHCl}_3/\text{EtOH}$ 4:1) λ_{max} 332 nm; ^1H NMR (400 MHz; CDCl_3) δ_{H} 0.88 (3H, t, $J = 6.8$


Hz), 0.95 (3H, t, $J = 7.4$ Hz), 1.25 (20H, m), 1.34 (2H, m), 1.66 (2H, m), 2.05 (2H, m), 2.21 (2H, t, $J = 7.4$ Hz), 2.31 (1H, br), 4.27 (2H, m), 4.37 (1H, dd, $J_1 = 11.3$ Hz, $J_2 = 3.5$ Hz), 4.45 (1H, dd, $J_1 = 11.3$ Hz, $J_2 = 5.9$ Hz), 5.26 (2H, m), 5.51 (1H, dd, $J_1 = 15.4$ Hz, $J_2 = 6.6$ Hz), 5.79 (1H, dt, $J_1 = 15.4$ Hz, $J_2 = 6.8$ Hz), 5.88 (1H, d, $J = 8.2$ Hz), 6.40 (1H, s), 7.02 (1H, s), 7.61 (1H, s); HRMS $[M+H]^+$ m/z calcd for $C_{33}H_{49}^{79}BrNO_8$ 666.2636, found 666.2644.

(2*S*,3*R*,4*E*)-2-Butyramidoctadec-4-ene-1,3-diyl bis(6-bromo-7-hydroxycoumarin-4-yl)methyl dicarbonate (10).




Yield 68%; UV ($CHCl_3/EtOH$ 4:1) λ_{max} 332 nm; 1H NMR (400 MHz; $CDCl_3$) δ_H 0.86 (3H, m), 0.93 (3H, m), 1.25 (20H, m), 1.35 (2H, m), 1.66 (2H, m), 2.02 (2H, m), 2.19 (2H, m), 4.15 (1H, m), 4.57 (2H, m), 4.84 (1H, m), 5.26 (4H, m), 5.36 (1H, m), 5.74 (1H, m), 5.90 (1H, m), 6.39 (1H, s), 6.41 (1H, s), 7.00 (1H, s), 7.02 (1H, s), 7.65 (1H, s), 7.67 (1H, s); HRMS $[M-H]^-$ m/z calcd for $C_{44}H_{52}^{79}Br_2NO_{13}$ 960.1811, found 960.1819.

(2*S*,3*R*,4*E*)-2-Palmitoylamido-3-hydroxyoctadec-4-enyl (6-bromo-7-hydroxycoumarin-4-yl)methyl carbonate (13).



Yield 70%; UV (CHCl₃/EtOH 4:1) λ_{max} 332 nm; ¹H NMR (400 MHz; CDCl₃) δ_{H} 0.88 (6H, t, J = 6.8 Hz), 1.25 (46H, m), 1.33 (2H, m), 1.62 (2H, m), 2.04 (2H, m), 2.20 (2H, m), 4.24 (2H, m), 4.35 (1H, dd, J_1 = 11.3 Hz, J_2 = 3.4 Hz), 4.47 (1H, dd, J_1 = 11.3 Hz, J_2 = 5.5 Hz), 5.26 (2H, m), 5.50 (1H, dd, J_1 = 15.5 Hz, J_2 = 6.6 Hz), 5.68 (1H, m), 5.85 (1H, d, J = 8.3 Hz), 6.40 (1H, s), 7.02 (1H, s), 7.61 (1H, s); HRMS [M-H]⁻ m/z calcd for C₄₅H₇₁⁷⁹BrNO₈ 832.4363, found 832.4362.

(2*S*,3*R*)-2-Palmitoylamido-3-hydroxyoctadecyl(6-bromo-7-hydroxycoumarin-4-yl)methyl carbonate (16).



Yield 72%; UV (CHCl₃/EtOH 4:1) λ_{max} 332 nm; ¹H NMR (400 MHz; CDCl₃) δ_{H} 0.88 (6H, t, J = 6.4 Hz), 1.25 (50H, m), 1.52 (2H, m), 1.63 (2H, m), 2.22 (2H, t, J = 7.8 Hz), 4.15 (1H, m), 4.39 (1H, dd, J_1 = 11.4 Hz, J_2 = 3.2 Hz), 4.43 (1H, m), 4.49 (1H, dd, J_1 = 11.5 Hz, J_2 = 5.2 Hz), 5.26 (2H, m), 5.95 (1H,

d, $J = 8.2$ Hz), 6.40 (1H, s), 7.02 (1H, s), 7.62 (1H, s); HRMS $[M-H]^-$ m/z calcd for $C_{45}H_{73}^{79}BrNO_8$ 834.4525, found 834.4515.

Preparation of silica-supported sodium hydrogen sulfate ($NaHSO_4 \cdot SiO_2$) catalyst.

A solution of sodium hydrogen sulfate monohydrate ($NaHSO_4 \cdot H_2O$, 1.04 g, 7.53 mmol) in water (5 mL) was treated with 2.50 g of silica gel (SiO_2 , 230-400 mesh, grade for column chromatography). The resulting mixture was stirred for 10 min and then was gently heated on a hot plate until the water was removed, providing $NaHSO_4 \cdot SiO_2$ as a free-flowing powder.^{S2} The catalyst was further dried and activated in an oven at 120 °C for 48 h before use.

Uptake of compound **16 into J774 macrophages.**

Mouse macrophages from the J774A.1 cell line were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum and antibiotics at 37 °C in a 5% CO_2 /95% air incubator. After the macrophages were incubated with 20 μ M **16** in KMops containing 5% EtOH for 2 h in the dark with shaking, the cells were gently washed with buffer and UV-irradiated for the time period indicated and imaged using a fluorescence microscope.




Fig. S1 UV-visible absorption spectra of Bhc-caged ceramides in $\text{CHCl}_3/\text{EtOH}$ (4:1). (a) compound **9**, (b) compound **10**, (c) compound **13**, and (d) compound **16**.





Fig. S2 Absorption (top) and fluorescence emission (bottom) spectra of **4** in KMops buffer, pH 7.4, (4A), and **4** and **16** in KMops containing 50% EtOH (4B and 16B, respectively).




Fig. S3 Uptake of compound **16** by macrophages and time course of photorelease of **4** upon photolysis. Bhc-caged C16-dihydroceramide (20 μM) was incubated with J774 macrophages in KMops buffer (pH 7.4) containing 5% EtOH final concentration (v/v) for 2 h in the dark with continuous shaking. Then the cells were gently washed with buffer and UV-irradiated at 350 nm for the time period indicated and imaged using a fluorescence microscope in the epifluorescence mode. All of the images are background-corrected and displayed on the same intensity scale with respect to the other images in the figure. Similar results were obtained with a lower concentration of **16** (5 μM).




Fig. S4 UV irradiation of J774 macrophages in the absence of **16** (control). Cells were incubated in KMops buffer, pH 7.4 (5% EtOH final concentration, v/v), in the absence of any Bhc-caged compound, and then UV-irradiated at 350 nm for the time periods indicated. All of the images are background-corrected and displayed on the same intensity scale with respect to the other images in the figure.





Fig. S5 Release of C16-dihydroceramide from **16** on photolysis at 350 nm. Compound **16** was photolyzed for 5 min in KMops buffer (pH 7.4) containing 50% EtOH. The chromatograms show the HPLC/MS analysis for the uncaging of compound **16** to afford C16-dihydroceramide. Eluent: 75% EtOH, 24.9% H₂O, 0.1% HCO₂H; flow rate, 0.2 mL/min; t_R of C16-dihydroceramide generated by photolysis, 7.5 min; t_R of a commercial sample of C16-ceramide, 7.3 min. MS $[M+H]^+$ m/z calcd for C₃₄H₇₀NO₃⁺ 540.5, found 540.5.

References

- S1 G. Jones II, W. R. Jackson and A. M. Halpern, *Chem. Phys. Lett.*, 1980, **72**, 391.
- S2 (a) G.W. Breton, *J. Org. Chem.*, 1997, **62**, 8952; (b) T. Nishiguchi and C. Kamio, *J. Chem. Soc., Perkin Trans. 1*, 1989, 707.





Data File	QCB BBB1033A.d	Sample Name	YAK-2-125-A
Sample Type	Sample	Position	P1-A4
Instrument Name	Instrument 1	User Name	
Acq Method		Acquired Time	11/4/2010 2:10:26 PM
IRM Calibration Status	Success	DA Method	HCEmpirical1.m
Comment	EM=709.2825 EM=HC HC ESI Pos Small Molecule No HPLC.m modified		

Compound Table

Compound Label	RT	Mass	Abund	Formula	Tgt Mass	Diff (ppm)
Cpd 2: C22H41NO2	0.228	351.3137	27816	C22H41NO2	351.3137	-0.07
Cpd 1: C35H52BrNO9	0.228	709.283	70492	C35H52BrNO9	709.2825	0.69

Compound Label	RT	Algorithm	Mass
Cpd 2: C22H41NO2	0.228	Find By Formula	351.3137





MS Spectrum Peak List

<i>m/z</i>	<i>Calc m/z</i>	Diff(ppm)	<i>z</i>	Abund	Formula	Ion
352.321	352.321	-0.07	1	27816	C22 H42 N O2	(M+H)+
353.3242	353.3243	-0.39	1	6768	C22 H42 N O2	(M+H)+
354.3261	354.3274	-3.66	1	1041	C22 H42 N O2	(M+H)+
710.2901				51228		
710.5246				1069		
<i>m/z</i>	<i>Calc m/z</i>	Diff(ppm)	<i>z</i>	Abund	Formula	Ion
711.2933				19367		
711.5324				432		
712.2892				55812		
712.5236				1333		
712.6349				487		
713.2917				19709		
713.526				611		
713.6711				372		
714.2944				5155		
715.2997				1052		

Compound Label	RT	Algorithm	Mass
Cpd 1: C35H52BrNO9	0.228	Find By Formula	709.283


MS Spectrum



MS Spectrum Peak List

<i>m/z</i>	<i>Calc m/z</i>	Diff(ppm)	z	Abund	Formula	Ion
692.2796	692.2793	0.47	1	2717	C35 H51 Br N O8	(M+H)+[-H2O]
694.278	694.2779	0.07	1	2737	C35 H51 Br N O8	(M+H)+[-H2O]
710.2901	710.2898	0.43		64687	C35 H53 Br N O9	(M+H)+
710.5245				1360		
711.2933	711.2932	0.21		24440	C35 H53 Br N O9	(M+H)+
712.2892	712.2885	1.01		70492	C35 H53 Br N O9	(M+H)+
712.5239				1692		
<i>m/z</i>	<i>Calc m/z</i>	Diff(ppm)	z	Abund	Formula	Ion
713.2917	713.2914	0.41		24895	C35 H53 Br N O9	(M+H)+
714.2949	714.2942	1.05		6478	C35 H53 Br N O9	(M+H)+
732.2716	732.2718	-0.26	1	26865	C35 H52 Br N Na O9	(M+Na)+
733.2752	733.2751	0.11	1	10142	C35 H52 Br N Na O9	(M+Na)+
734.2705	734.2704	0.07	1	28693	C35 H52 Br N Na O9	(M+Na)+
735.2737	735.2734	0.41	1	10369	C35 H52 Br N Na O9	(M+Na)+
736.2765	736.2761	0.51	1	2804	C35 H52 Br N Na O9	(M+Na)+
748.2491	748.2457	4.6	1	1067	C35 H52 Br K N O9	(M+K)+

--- End Of Report ---





Data File	QCBBBB1048A.d	Sample Name	YAK-3-3-B
Sample Type	Sample	Position	P1-A2
Instrument Name	Instrument 1	User Name	
Acq Method		Acquired Time	11/24/2010 10:08:47 AM
IRM Calibration Status	Success	DA Method	HCEmpirical1.m
Comment	EM=1049.2408 EM=HC HC ESI Pos Small Molecule No HPLC.m		

Compound Table

Compound Label	RT	Mass	Abund	Formula	Tgt Mass	Diff (ppm)
Cpd 1: C48H61Br2NO15	0.235	1049.2417	35498	C48H61Br2NO15	1049.2408	0.89


Compound Label	RT	Algorithm	Mass
Cpd 1: C48H61Br2NO15	0.235	Find By Formula	1049.2417



MS Spectrum Peak List

<i>m/z</i>	<i>Calc m/z</i>	Diff(ppm)	<i>z</i>	Abund	Formula	Ion
1050.247	1050.2481	-0.99	1	3053	C48 H62 Br2 N O15	(M+H)+
1052.2474	1052.2467	0.65	1	6838	C48 H62 Br2 N O15	(M+H)+
1053.2496	1053.2497	-0.04	1	3387	C48 H62 Br2 N O15	(M+H)+
1054.2465	1054.2462	0.23	1	3952	C48 H62 Br2 N O15	(M+H)+
1055.2479	1055.2484	-0.52	1	1790	C48 H62 Br2 N O15	(M+H)+
<i>m/z</i>	<i>Calc m/z</i>	Diff(ppm)	<i>z</i>	Abund	Formula	Ion
1067.2749	1067.2746	0.28		14429	C48 H65 Br2 N2 O15	(M+NH4)+
1068.2782	1068.2779	0.26		7296	C48 H65 Br2 N2 O15	(M+NH4)+
1069.2744	1069.2733	1.12		35498	C48 H65 Br2 N2 O15	(M+NH4)+
1070.2766	1070.2762	0.42		16409	C48 H65 Br2 N2 O15	(M+NH4)+
1071.2734	1071.2728	0.56		19849	C48 H65 Br2 N2 O15	(M+NH4)+
1072.2704	1072.2749	-4.26		9408	C48 H65 Br2 N2 O15	(M+NH4)+
1073.2685	1073.2774	-8.31		2942	C48 H65 Br2 N2 O15	(M+NH4)+
1074.2338	1074.2286	4.79		3319	C48 H61 Br2 N Na O15	(M+Na)+
1075.2343	1075.2316	2.45	1	1679	C48 H61 Br2 N Na O15	(M+Na)+
1076.2278	1076.2282	-0.38	1	1848	C48 H61 Br2 N Na O15	(M+Na)+

--- End Of Report ---



Data File

Sample Type

Instrument Name

Acq Method

IRM Calibration Status

Comment

QCBBBB1078A.d

Sample

Instrument 1

Success

EM=877.4703 M=HC ESI

Pos Small Molecule No

HPLC.m

12

Sample Name

YAK-3-97

Position

P1-A1

User Name

Acquired Time

3/8/2011 4:56:46

PM



DA Method

HCEmpirical1.m

Compound Table

Compound Label	RT	Mass	Abund	Formula	Tgt Mass	Diff (ppm)
Cpd 1: C47H76BrNO9	0.231	877.4699	38608	C47H76BrNO9	877.4703	-0.53


Compound Label	RT	Algorithm	Mass
Cpd 1: C47H76BrNO9	0.231	Find By Formula	877.4699



MS Spectrum Peak List

<i>m/z</i>	<i>Calc m/z</i>	Diff(ppm)	z	Abund	Formula	Ion
860.4649	860.4671	-2.5	1	768	C47 H75 Br N O8	(M+H)+[-H2O]
862.4641	862.4662	-2.43	1	847	C47 H75 Br N O8	(M+H)+[-H2O]
878.4772	878.4776	-0.52		33882	C47 H77 Br N O9	(M+H)+
879.4803	879.481	-0.77		17432	C47 H77 Br N O9	(M+H)+
880.4763	880.4767	-0.49		38608	C47 H77 Br N O9	(M+H)+
880.7381				967		
<i>m/z</i>	<i>Calc m/z</i>	Diff(ppm)	z	Abund	Formula	Ion
881.4788	881.4794	-0.73		17926	C47 H77 Br N O9	(M+H)+
882.4811	882.4823	-1.29		5170	C47 H77 Br N O9	(M+H)+
883.4844	883.4851	-0.81		1144	C47 H77 Br N O9	(M+H)+
900.4588	900.4596	-0.84	1	3842	C47 H76 Br N Na O9	(M+Na)+
901.4622	901.4629	-0.81	1	1991	C47 H76 Br N Na O9	(M+Na)+
902.4579	902.4587	-0.9	1	4205	C47 H76 Br N Na O9	(M+Na)+
903.4603	903.4614	-1.22	1	2057	C47 H76 Br N Na O9	(M+Na)+
904.4634	904.4642	-0.88	1	664	C47 H76 Br N Na O9	(M+Na)+
916.4351	916.4335	1.8	1	133	C47 H76 Br K N O9	(M+K)+

--- End Of Report ---





Data File	QCBBBB1069A.d	15	Sample Name	YAK-3-71-A
Sample Type	Sample		Position	P1-A1
Instrument Name	Instrument 1		User Name	
Acq Method			Acquired Time	1/27/2011 7:12:01 PM
IRM Calibration Status	Success		DA Method	HCEmpirical1.m
Comment	EM=879.4860 M=HC ESI Pos Small Molecule No HPLC.m			

Compound Table

Compound Label	RT	Mass	Abund	Formula	Tgt Mass	Diff (ppm)
Cpd 1: C47H78BrNO9	0.231	879.4867	115872	C47H78BrNO9	879.486	0.84


Compound Label	RT	Algorithm	Mass
Cpd 1: C47H78BrNO9	0.231	Find By Formula	879.4867



MS Spectrum Peak List

<i>m/z</i>	<i>Calc m/z</i>	Diff(ppm)	z	Abund	Formula	Ion
880.4941	880.4933	0.89		100528	C47 H79 Br N O9	(M+H)+
880.7491				2458		
881.4972	881.4966	0.62		51340	C47 H79 Br N O9	(M+H)+
882.4932	882.4924	0.87		115872	C47 H79 Br N O9	(M+H)+
882.7505				3482		
882.8697				1755		
<i>m/z</i>	<i>Calc m/z</i>	Diff(ppm)	z	Abund	Formula	Ion
883.4956	883.4951	0.64		53800	C47 H79 Br N O9	(M+H)+
884.498	884.4979	0.06		14673	C47 H79 Br N O9	(M+H)+
885.5005	885.5008	-0.3		3243	C47 H79 Br N O9	(M+H)+
902.4748	902.4752	-0.48	1	20760	C47 H78 Br N Na O9	(M+Na)+
903.4785	903.4786	-0.12	1	10688	C47 H78 Br N Na O9	(M+Na)+
904.4742	904.4743	-0.15	1	23276	C47 H78 Br N Na O9	(M+Na)+
905.4766	905.477	-0.44	1	11335	C47 H78 Br N Na O9	(M+Na)+
906.479	906.4799	-0.97	1	3136	C47 H78 Br N Na O9	(M+Na)+
918.4506	918.4492	1.63	1	1049	C47 H78 Br K N O9	(M+K)+

--- End Of Report ---





Data File	QCBBBB1047A.d	Sample Name	YAK-3-27
Sample Type	Sample	Position	P1-A1
Instrument Name	Instrument 1	User Name	
Acq Method		Acquired Time	11/24/2010 9:57:25 AM
IRM Calibration Status	Success	DA Method	HCEmpirical1.m
Comment	EM=665.2563 EM=HC HC ESI Pos Small Molecule No HPLC.m		

Compound Table

Compound Label	RT	Mass	Abund	Formula	Tgt Mass	Diff (ppm)
Cpd 1: C33H48BrNO8	0.228	665.2573	34225	C33H48BrNO8	665.2563	1.47


Compound Label	RT	Algorithm	Mass
Cpd 1: C33H48BrNO8	0.228	Find By Formula	665.2573



MS Spectrum Peak List

<i>m/z</i>	<i>Calc m/z</i>	Diff(ppm)	z	Abund	Formula	Ion
648.2534	648.253	0.6	1	1438	C33 H47 Br N O7	(M+H)+[-H2O]
649.2578	649.2564	2.23	1	564	C33 H47 Br N O7	(M+H)+[-H2O]
650.2518	650.2516	0.24	1	1542	C33 H47 Br N O7	(M+H)+[-H2O]
651.2556	651.2546	1.53	1	542	C33 H47 Br N O7	(M+H)+[-H2O]
666.2644	666.2636	1.16		31583	C33 H49 Br N O8	(M+H)+
667.2673	667.267	0.58		10627	C33 H49 Br N O8	(M+H)+
<i>m/z</i>	<i>Calc m/z</i>	Diff(ppm)	z	Abund	Formula	Ion
668.2634	668.2622	1.75		34225	C33 H49 Br N O8	(M+H)+
669.2657	669.2652	0.83		10830	C33 H49 Br N O8	(M+H)+
670.2697	670.2679	2.62		2634	C33 H49 Br N O8	(M+H)+
671.2729	671.2706	3.31		505	C33 H49 Br N O8	(M+H)+
688.246	688.2456	0.6	1	3834	C33 H48 Br N Na O8	(M+Na)+
689.2494	689.2489	0.67	1	1493	C33 H48 Br N Na O8	(M+Na)+
690.2444	690.2442	0.37	1	4122	C33 H48 Br N Na O8	(M+Na)+
691.2474	691.2471	0.33	1	1451	C33 H48 Br N Na O8	(M+Na)+
704.2153	704.2195	-5.95	1	130	C33 H48 Br K N O8	(M+K)+

--- End Of Report ---





Data File	QCB BBB1067C.d	Sample Name	YAK-3-61
Sample Type	Sample	Position	P1-A6
Instrument Name	Instrument 1	User Name	
Acq Method		Acquired Time	1/4/2011 12:55:40 PM
IRM Calibration Status	Success	DA Method	HCEmpirical1.m
Comment	EM=961.1884 EM=HC ESI Pos Small Molecule No HPLC.m		

Compound Table

Compound Label	RT	Mass	Abund	Formula	Tgt Mass	Diff (ppm)
Cpd 1: C44H53Br2NO13	0.237	961.1867	334	C44H53Br2NO13	961.1884	-1.71


Compound Label	RT	Algorithm	Mass
Cpd 1: C44H53Br2NO13	0.237	Find By Formula	961.1867



MS Spectrum Peak List

<i>m/z</i>	<i>Calc m/z</i>	<i>Diff(ppm)</i>	<i>z</i>	<i>Abund</i>	<i>Formula</i>	<i>Ion</i>
112.9857				5060		
113.9891				125		
114.9975				84		
117.0193				417		
479.5849	479.5869	-4.12	-2	173	C44 H51 Br2 N O13	(M-2H)-2
<i>m/z</i>	<i>Calc m/z</i>	<i>Diff(ppm)</i>	<i>z</i>	<i>Abund</i>	<i>Formula</i>	<i>Ion</i>
480.5851	480.5862	-2.24	-2	334	C44 H51 Br2 N O13	(M-2H)-2
481.0865	481.0877	-2.56	-2	161	C44 H51 Br2 N O13	(M-2H)-2
481.5847	481.5858	-2.37	-2	232	C44 H51 Br2 N O13	(M-2H)-2
482.0843	482.087	-5.65	-2	81	C44 H51 Br2 N O13	(M-2H)-2
960.1819	960.1811	0.83	-1	174	C44 H52 Br2 N O13	(M-H)-
961.181	961.1844	-3.57	-1	100	C44 H52 Br2 N O13	(M-H)-
962.1775	962.1796	-2.22	-1	368	C44 H52 Br2 N O13	(M-H)-
963.1793	963.1826	-3.47	-1	184	C44 H52 Br2 N O13	(M-H)-
964.1769	964.179	-2.13	-1	226	C44 H52 Br2 N O13	(M-H)-
965.1807	965.1813	-0.61	-1	102	C44 H52 Br2 N O13	(M-H)-

--- End Of Report ---





Data File	QCB BBB1081B.d	Sample Name	YAK-3-111
Sample Type	Sample	Position	P1-A1
Instrument Name	Instrument 1	User Name	
Acq Method		Acquired Time	3/21/2011 1:10:44 PM
IRM Calibration Status	Success	DA Method	HCEmpirical1.m
Comment	EM=833.4441 M=HC ESI Pos Small Molecule No HPLC.m		

Compound Table

Compound Label	RT	Mass	Abund	Formula	Tgt Mass	Diff (ppm)	MFG Formula	DB Formula
Cpd 1:	0.234	833.4433	25036	C45H72BrNO8	833.4441	-1.03	C45H72BrNO8	C45H72BrNO8


Compound Label	m/z	RT	Algorithm	Mass
Cpd 1:	951.4224	0.234	Find By Formula	833.4433



MS Spectrum Peak List

<i>m/z</i>	<i>Calc m/z</i>	<i>Diff(ppm)</i>	<i>z</i>	<i>Abund</i>	<i>Formula</i>	<i>Ion</i>
252.9492			1	1455.9		
254.9437			1	1683.2		
582.5093			1	2045.6		
650.4964			1	3049.5		
651.5			1	1193		
832.4362	832.4369	-0.81	1	22411	C45H71BrNO8	(M-H)-
833.439	833.4402	-1.48	1	10976	C45H71BrNO8	(M-H)-
834.4349	834.4359	-1.16	1	25036	C45H71BrNO8	(M-H)-
835.4379	835.4386	-0.9	1	11384	C45H71BrNO8	(M-H)-
836.4406	836.4415	-1.08	1	3187.5	C45H71BrNO8	(M-H)-
878.4604			1	1004.7		
946.4283	946.4297	-1.46	1	1830.3	C47H72BrF3NO10	(M+CF3COO)-
947.4315	947.4331	-1.69	1	968.6	C47H72BrF3NO10	(M+CF3COO)-
948.4273	948.4288	-1.65	1	2094.3	C47H72BrF3NO10	(M+CF3COO)-
949.4293	949.4315	-2.35	1	985.6	C47H72BrF3NO10	(M+CF3COO)-

--- End Of Report ---





Data File	QCBBBB1070B.d	Sample Name	YAK-3-73
Sample Type	Sample	Position	P1-A1
Instrument Name	Instrument 1	User Name	
Acq Method		Acquired Time	2/9/2011 5:29:02 PM
IRM Calibration Status	Success	DA Method	HCEmpirical1.m
Comment	EM=835.4598 M=HC ESI Pos Small Molecule No HPLC.m		

Compound Table

Compound Label	RT	Mass	Abund	Formula	Tgt Mass	Diff (ppm)
Cpd 1: C45H74BrNO8	0.241	835.4588	10310	C45H74BrNO8	835.4598	-1.16

Compound Label	RT	Algorithm	Mass
Cpd 1: C45H74BrNO8	0.241	Find By Formula	835.4588




MS Spectrum Peak List


<i>m/z</i>	<i>Calc m/z</i>	<i>Diff(ppm)</i>	<i>z</i>	<i>Abund</i>	<i>Formula</i>	<i>Ion</i>
834.4515	834.4525	-1.19		9053	C45 H73 Br N O8	(M-H)-
834.7077				100		
835.4545	835.4559	-1.62		4412	C45 H73 Br N O8	(M-H)-
835.7118				94		
836.4506	836.4515	-1.12		10310	C45 H73 Br N O8	(M-H)-
836.7128				105		
<i>m/z</i>	<i>Calc m/z</i>	<i>Diff(ppm)</i>	<i>z</i>	<i>Abund</i>	<i>Formula</i>	<i>Ion</i>
837.4534	837.4543	-1.01		4556	C45 H73 Br N O8	(M-H)-
837.7141				83		
837.7938				80		
838.4555	838.4571	-2.01		1247	C45 H73 Br N O8	(M-H)-
839.4595	839.46	-0.59		263	C45 H73 Br N O8	(M-H)-
948.4424	948.4454	-3.13	1	280	C47 H74 Br F3 N O10	(M+CF3COO)-
949.4443	949.4487	-4.64	1	158	C47 H74 Br F3 N O10	(M+CF3COO)-
950.4444	950.4445	-0.1	1	304	C47 H74 Br F3 N O10	(M+CF3COO)-
951.4445	951.4472	-2.77	1	166	C47 H74 Br F3 N O10	(M+CF3COO)-

--- End Of Report ---

SpinWorks 3: PROTON DMSO /opt/topspin1.3 guest 25




SpinWorks 3: c13cpd_night DMSO /opt/topspin1.3 guest 25




file: ...oumarin_1H_13C\yak-2-5-DMSO\11\fid expt: <zpgp30>
transmitterfreq: 100.622830 MHz
time domain size: 65536 points
width: 23980.82 Hz = 238.3238 ppm = 0.365918 Hz/pt
number of scans: 4096


freq. of 0 ppm: 100.612814 MHz
processed size: 32768 complex points
LB: 1.000 GF: 0.0000
Hz/cm: 507.775 ppm/cm: 5.04632

SpinWorks 3: PROTON MeOD /opt/topspin1.3 guest 28






SpinWorks 3: PROTON CDCl3 /opt/topspin1.3 guest 38




SpinWorks 3: c13cpd_night CDCl3 /opt/topspin1.3 guest 38




file: ...oumarin_1H_13C\yak-10092010\11\fid exp: <zpgp30>
transmitterfreq: 100.622830 MHz
time domain size: 65536 points
width: 23980.82 Hz = 238.3238 ppm = 0.365918 Hz/pt
number of scans: 4096

freq. of 0 ppm: 100.612756 MHz
processed size: 32768 complex points
LB: 1.000 GF: 0.0000
Hz/cm: 482.848 ppm/cm: 4.79859

SpinWorks 3: PROTON CDCl3 /opt/topspin1.3 guest 15




SpinWorks 3: c13cpd_night CDCl3 /opt/topspin1.3 guest 15




file: ...ou-chloroformate\YAK-2-121C\20\fid exp: <zgpg30>
transmitterfreq.: 100.622830 MHz
time domain size: 65536 points
width: 23980.82 Hz = 238.3238 ppm = 0.365918 Hz/pt
number of scans: 4096
freq. of 0 ppm: 100.612756 MHz
processed size: 32768 complex points
LB: 1.000 GF: 0.0000
Hz/cm: 449.611 ppm/cm: 4.46828

SpinWorks 3: PROTON CDC13 /opt/topspin1.3 guest 8




SpinWorks 3: c13cpd_night CDC13 /opt/topspin1.3 guest 8




file: ..._13C\yak11012010_need_check\11\fid expt: <zpgp30>
transmitterfreq: 100.622830 MHz
time domain size: 65536 points
width: 23980.82 Hz = 238.3238 ppm = 0.365918 Hz/pt
number of scans: 6144


freq. of 0 ppm: 100.612757 MHz
processed size: 32768 complex points
LB: 1.000 GF: 0.0000
Hz/cm: 684.111 ppm/cm: 6.79877


SpinWorks 3: PROTON CDC13 /opt/topspin1.3 guest 27




SpinWorks 3: c13cpd_night CDCl3 /opt/topspin1.3 guest 27









SpinWorks 3: PROTON CDC13 /opt/topspin1.3 guest 3



SpinWorks 3: c13cpd_night CDC13 /opt/topspin1.3 guest 3




SpinWorks 3: PROTON CDCl3 /opt/topspin1.3 guest 10



file: ...amide(Final)_1H\yak11162010\10\fid expt: <zg30>
transmitterfreq: 400.132471 MHz
time domain size: 65536 points
width: 8278.15 Hz = 20.6885 ppm = 0.126314 Hz/pt
number of scans: 16
freq. of 0 ppm: 400.130008 MHz
processed size: 32768 complex points
LB: 0.300 GF: 0.0000
Hz/cm: 130.666 ppm/cm: 0.32656


SpinWorks 3: PROTON CDC13 /opt/topspin1.3 guest 3



file:...\nal)_1H\YAK-3-61.need.check\10\fid expt: <zg30>
transmitterfreq: 400.132471 MHz
time domain size: 65536 points
width: 8278.15 Hz = 20.6885 ppm = 0.126314 Hz/pt
number of scans: 80


freq. of 0 ppm: 400.130009 MHz
processed size: 32768 complex points
LB: 0.300 GF: 0.0000
Hz/cm: 134.490 ppm/cm: 0.33611

SpinWorks 3: YAK-3-111



file: F:\500NMR\yak03162011\1\fid exp: <zg30>
transmitterfreq.: 500.133089 MHz
time domain size: 65536 points
width: 10330.58 Hz = 20.6557 ppm = 0.157632 Hz/pt
number of scans: 16
freq. of 0 ppm: 500.130012 MHz
processed size: 32768 complex points
LB: 0.300 GF: 0.0000
Hz/cm: 163.857 ppm/cm: 0.32763

SpinWorks 3: PROTON CDC13 /opt/topspin1.3 guest 14



file: ...eramide.(Final)_1H\YAK-3-73\10\fid exp: <zg30>
transmitter freq.: 400.132471 MHz
time domain size: 65536 points
width: 8278.15 Hz = 20.6885 ppm = 0.126314 Hz/pt
number of scans: 24

freq. of 0 ppm: 400.130009 MHz
processed size: 32768 complex points
LB: 0.300 GF: 0.0000
Hz/cm: 176.877 ppm/cm: 0.44205